Kissei Pharmaceutical Co., Ltd. 4547

The latest analyst update on Rigel Pharmaceuticals centers on a higher assessed fair value, which has moved from US$51.6 to US$61.2 per share in the current model. Analysts link this shift to how they view Veppanu in the U.S. and the ex U.S. potential of Rezlidhia under the Kissei partnership, with both products seen as key to supporting or challenging the new valuation. As you read on, you will see how to track this evolving narrative and what it could mean for your own view of Rigel...

Kissei Pharmaceutical (TSE:4547) cut its earnings guidance for the six months to September 2026 and the full year to March 2027 after TAVNEOS sales lagged expectations, affecting revenue forecasts and projected profitability. See our latest analysis for Kissei Pharmaceutical. The earnings guidance cut has come as Kissei Pharmaceutical’s share price sits at ¥4,160, with a 1-day share price return of 3.74% and a year-to-date share price return that is down 9.86%. The 5-year total shareholder...

Amgen Inc.’s (NASDAQ:AMGN) Japanese partner Kissei Pharmaceutical Co., Ltd. said it has started information-sharing activities in Japan, urging healthcare professionals to carefully evaluate the use of Tavneos (avacopan) following safety and regulatory concerns raised in the U.S. and Europe. Kissei Advises Doctors To Exercise Caution On Tavneos The company said physicians should avoid prescribing the drug to new patients and reassess continued treatment for current users while considering risks

Recently published Endometriosis Market Insights report includes a comprehensive understanding of current treatment practices, endometriosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].